Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omri Wolk

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Chemical Information and Modeling|December 13, 2022
Predicting the Likelihood of Molecules to Act as Modulators of Protein-Protein InteractionsOmri Wolk, Amiram Goldblum
Drug Design, Development and Therapy|October 7, 2014
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product developmentOmri Wolk, Riad Agbaria, Arik Dahan
Molecular Pharmaceutics|April 17, 2014
The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalolMoran Zur, Marisa Gasparini, Omri Wolk, et al.
Expert Opinion on Drug Delivery|June 1, 2013
New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunitiesOmri Wolk, Svetlana Epstein, Viktoriya Ioffe-Dahan, et al.
Journal of Pharmaceutical Sciences|July 29, 2018
Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability ValuesOmri Wolk, Milica Markovic, Daniel Porat, et al.
Molecular Pharmaceutics|November 4, 2014
Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancersArik Dahan, Omri Wolk, Peihua Yang, et al.
Molecular Pharmaceutics|October 8, 2013
Purely in silico BCS classification: science based quality standards for the world's drugsArik Dahan, Omri Wolk, Young Hoon Kim, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|June 24, 2016
Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendationsCarmil Azran, Omri Wolk, Moran Zur, et al.
International Journal of Pharmaceutics|January 18, 2015
In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approachesIsabel Lozoya-Agullo, Moran Zur, Omri Wolk, et al.
Frontiers in Cell and Developmental Biology|April 28, 2022
<i>In silico</i> Docking Analysis for Blocking JUNO-IZUMO1 Interaction Identifies Two Small Molecules that Block <i>in vitro</i> FertilizationNataliia Stepanenko, Omri Wolk, Enrica Bianchi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Chemical Information and Modeling|December 13, 2022
Predicting the Likelihood of Molecules to Act as Modulators of Protein-Protein InteractionsOmri Wolk, Amiram Goldblum
Drug Design, Development and Therapy|October 7, 2014
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product developmentOmri Wolk, Riad Agbaria, Arik Dahan
Molecular Pharmaceutics|April 17, 2014
The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalolMoran Zur, Marisa Gasparini, Omri Wolk, et al.
Expert Opinion on Drug Delivery|June 1, 2013
New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunitiesOmri Wolk, Svetlana Epstein, Viktoriya Ioffe-Dahan, et al.
Journal of Pharmaceutical Sciences|July 29, 2018
Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability ValuesOmri Wolk, Milica Markovic, Daniel Porat, et al.
Molecular Pharmaceutics|November 4, 2014
Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancersArik Dahan, Omri Wolk, Peihua Yang, et al.
Molecular Pharmaceutics|October 8, 2013
Purely in silico BCS classification: science based quality standards for the world's drugsArik Dahan, Omri Wolk, Young Hoon Kim, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|June 24, 2016
Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendationsCarmil Azran, Omri Wolk, Moran Zur, et al.
International Journal of Pharmaceutics|January 18, 2015
In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approachesIsabel Lozoya-Agullo, Moran Zur, Omri Wolk, et al.
Frontiers in Cell and Developmental Biology|April 28, 2022
<i>In silico</i> Docking Analysis for Blocking JUNO-IZUMO1 Interaction Identifies Two Small Molecules that Block <i>in vitro</i> FertilizationNataliia Stepanenko, Omri Wolk, Enrica Bianchi, et al.
Pageof 2